Adverse effects after treatment initiation: infections · children diagnosed with Kawasaki disease
TNF‐α blockers intervention showed no clear difference in adverse effects after treatment initiation: infections compared with placebo or additional treatment (low certainty).
1 finding from 1 review
Diarrhoea · women with obesity during pregnancy
Metformin leads to higher adverse effects associated with the treatment: diarrhoea compared with placebo (high certainty).
1 finding from 1 review
Ataxia · people with focal epilepsy
Zonisamide may leads to higher adverse effects: ataxia (whole treatment period; any dose) compared with placebo (low certainty).
1 finding from 1 review
Nausea · people with focal epilepsy
Zonisamide probably leads to higher adverse effects: nausea (whole treatment period; any dose) compared with placebo (moderate certainty).
1 finding from 1 review
Adverse effect: fatigue · people with focal epilepsy
Zonisamide probably leads to higher adverse effects: fatigue (whole treatment period; any dose) compared with placebo (moderate certainty).
1 finding from 1 review
Intervention not reported
Adverse effects of medication, at any time during treatment · children with blepharokeratoconjunctivitis
1 finding from 1 review
Adverse effects during treatment ‐ heaviness in lower abdomen · endometrial hyperplasia
It is very uncertain whether summary of findings table ‐ Metformin + levonorgestrel (intrauterine… changes adverse effects during treatment ‐ heaviness in lower abdomen compared with levonorgestrel intrauterine system (very low certainty).
1 finding from 1 review
Incidence of any adverse effects after treatment initiation ( · people undergoing initial treatment for KD
Primary treatment with intravenous immunoglobulin (IVIG) showed no clear difference in incidence of any adverse effects after treatment initiation ( compared with different infusion regimens of IVIG (low certainty).
1 finding from 1 review
Frequency of adverse effects ‐ dizziness ( · people with focal epilepsy
Zonisamide probably leads to higher adverse effects: dizziness (whole treatment period; any dose) compared with placebo (moderate certainty).
1 finding from 1 review
Withdrawals due to adverse events · workers at risk of occupational irritant hand dermatitis
1 finding from 1 review
Withdrawals due to adverse events · workers at risk of occupational irritant hand dermatitis
1 finding from 1 review
Withdrawals due to adverse events · workers at risk of occupational irritant hand dermatitis
1 finding from 1 review
Withdrawals due to adverse events · workers at risk of occupational irritant hand dermatitis
1 finding from 1 review
Somnolence · people with focal epilepsy
Zonisamide probably leads to higher adverse effects: somnolence (whole treatment period; any dose) compared with placebo (moderate certainty).
1 finding from 1 review
Adverse effects Timing of outcome assessment: end of treatment · patients with borderline personality disorder
Psychotherapy showed no clear difference in adverse effects Timing of outcome assessment: end of treatment compared with treatment‐as‐usual (low certainty).
1 finding from 1 review
Infusion reactions · children diagnosed with Kawasaki disease
TNF‐α blockers intervention may leads to lower adverse effects after treatment initiation: infusion reactions compared with placebo or additional treatment (low certainty).
1 finding from 1 review
Adverse effects of treatment Overall incidence of complications · people with lateral patellar dislocation
It is very uncertain whether surgical changes adverse effects of treatment Overall incidence of complications compared with non‐surgical treatment (very low certainty).
1 finding from 1 review
Ataxia · people (aged 10–64 years) with drug‐resistant focal epilepsy
It is very uncertain whether vigabatrin changes adverse effects: ataxia Duration of treatment (range): 7–36 weeks compared with placebo (very low certainty).
1 finding from 1 review
Adverse effect: fatigue · people (aged 10–64 years) with drug‐resistant focal epilepsy
Vigabatrin may leads to higher adverse effects: fatigue Duration of treatment (range): 8–36 weeks compared with placebo (low certainty).
1 finding from 1 review
Adverse effects during antidepressant treatment period (0‐12 weeks) · adults living with HIV and depression
It is very uncertain whether selective serotonin reuptake inhibitors (SSRI) changes adverse effects during antidepressant treatment period (0‐12 weeks) compared with tricyclic antidepressant (TCA) (very low certainty).
1 finding from 1 review